Hydreight Technologies (TSXV: NURS) is a Nurses on Demand telehealth platform that provides clients with personalized healthcare treatments which is a legally compliant way to provide low-cost semaglutide through their compounding pharmacy partners . Unfortunately for Hims & Hers (HIMS) most of their customers are receiving commercially available doses of semaglutide : 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg. NURS has an opportunity to capture a significant percentage of HIMS market share !
Read this tweet on X from the CEO of HIMS last night click here! HIMS is driving away clients to NURS!
NURS revenue grew by 46%+ year-over-year last quarter and NURS has generated positive cash flow over the last nine months!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA has received compensation from NURS of US$30,000 cash for a three-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
